Serum FSTL3 significantly increased in patients with high NAFLD fibrosis risk and AMI, and closely associated with NAFLD fibrosis and AMI severity in T2DM patients with co-existent NAFLD. This evidence concerns the gene FSTL3 and metabolic dysfunction-associated steatotic liver disease.